

# Fulvio Baggi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4606432/publications.pdf>

Version: 2024-02-01

86  
papers

2,858  
citations

159585

30  
h-index

182427

51  
g-index

87  
all docs

87  
docs citations

87  
times ranked

3838  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Alpha-Synuclein RT-QuIC Products Generated by the Olfactory Mucosa of Patients with Parkinson's Disease and Multiple System Atrophy Induce Inflammatory Responses in SH-SY5Y Cells. <i>Cells</i> , 2022, 11, 87.	4.1	5
2	CD146+ Pericytes Subset Isolated from Human Micro-Fragmented Fat Tissue Display a Strong Interaction with Endothelial Cells: A Potential Cell Target for Therapeutic Angiogenesis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5806.	4.1	7
3	Complement Activation Profile in Myasthenia Gravis Patients: Perspectives for Tailoring Anti-Complement Therapy. <i>Biomedicines</i> , 2022, 10, 1360.	3.2	1
4	Halogenation of the N-Terminus Tyrosine 10 Promotes Supramolecular Stabilization of the Amyloid- $\beta$ Sequence 7-12. <i>ChemistryOpen</i> , 2020, 9, 253-260.	1.9	6
5	Enhanced self-assembly of the 7-12 sequence of amyloid- $\beta$ peptide by tyrosine bromination. <i>Supramolecular Chemistry</i> , 2020, 32, 247-255.	1.2	8
6	242nd ENMC International Workshop: Diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1-3 March 2019. <i>Neuromuscular Disorders</i> , 2020, 30, 254-264.	0.6	12
7	7-T MRI tracking of mesenchymal stromal cells after lung injection in a rat model. <i>European Radiology Experimental</i> , 2020, 4, 54.	3.4	5
8	Therapeutic Effect of Bifidobacterium Administration on Experimental Autoimmune Myasthenia Gravis in Lewis Rats. <i>Frontiers in Immunology</i> , 2019, 10, 2949.	4.8	22
9	Autoantibody Diagnostics in Neuroimmunology: Experience From the 2018 Italian Neuroimmunology Association External Quality Assessment Program. <i>Frontiers in Neurology</i> , 2019, 10, 1385.	2.4	26
10	Toll-like receptors 7 and 9 in myasthenia gravis thymus: amplifiers of autoimmunity?. <i>Annals of the New York Academy of Sciences</i> , 2018, 1413, 11-24.	3.8	28
11	Gut microbiota and probiotics: novel immune system modulators in myasthenia gravis?. <i>Annals of the New York Academy of Sciences</i> , 2018, 1413, 49-58.	3.8	36
12	LYVE-1 is 'on stage' now: an emerging player in dendritic cell docking to lymphatic endothelial cells. <i>Cellular and Molecular Immunology</i> , 2018, 15, 663-665.	10.5	6
13	Administration of bifidobacterium and lactobacillus strains modulates experimental myasthenia gravis and experimental encephalomyelitis in Lewis rats. <i>Oncotarget</i> , 2018, 9, 22269-22287.	1.8	38
14	A propensity score analysis for comparison of T-3b and VATET in myasthenia gravis. <i>Neurology</i> , 2017, 89, 189-195.	1.1	11
15	Validation of the italian version of the 15-item Myasthenia Gravis Quality of Life questionnaire. <i>Muscle and Nerve</i> , 2017, 56, 716-720.	2.2	8
16	Diagnostics of myasthenic syndromes: detection of anti-AChR and anti-MuSK antibodies. <i>Neurological Sciences</i> , 2017, 38, 253-257.	1.9	12
17	Suppression of CHRN endocytosis by carbonic anhydrase CAR3 in the pathogenesis of myasthenia gravis. <i>Autophagy</i> , 2017, 13, 1981-1994.	9.1	14
18	Validity, reliability, and sensitivity to change of the myasthenia gravis activities of daily living profile in a sample of Italian myasthenic patients. <i>Neurological Sciences</i> , 2017, 38, 1927-1931.	1.9	5

#	ARTICLE	IF	CITATIONS
19	In vitro labelling and detection of mesenchymal stromal cells: a comparison between magnetic resonance imaging of iron-labelled cells and magnetic resonance spectroscopy of fluorine-labelled cells. <i>European Radiology Experimental</i> , 2017, 1, 6.	3.4	6
20	Epstein-Barr virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an autoimmunity mediator?. <i>Oncotarget</i> , 2017, 8, 95432-95449.	1.8	23
21	A Novel Approach to Reinstating Tolerance in Experimental Autoimmune Myasthenia Gravis Using a Targeted Fusion Protein, mCTA1 $\alpha$ T146. <i>Frontiers in Immunology</i> , 2017, 8, 1133.	4.8	10
22	Animal models of myasthenia gravis: utility and limitations. <i>International Journal of General Medicine</i> , 2016, 9, 53.	1.8	32
23	Identification of a gene expression signature in peripheral blood of multiple sclerosis patients treated with disease-modifying therapies. <i>Clinical Immunology</i> , 2016, 173, 133-146.	3.2	9
24	Validation of the besta neurological institute rating scale for myasthenia gravis. <i>Muscle and Nerve</i> , 2016, 53, 32-37.	2.2	11
25	A novel infection- and inflammation-associated molecular signature in peripheral blood of myasthenia gravis patients. <i>Immunobiology</i> , 2016, 221, 1227-1236.	1.9	33
26	Increased expression of Toll-like receptors 7 and 9 in myasthenia gravis thymus characterized by active Epstein-Barr virus infection. <i>Immunobiology</i> , 2016, 221, 516-527.	1.9	47
27	<i>In vivo</i> quantitative magnetization transfer imaging correlates with histology during de- and remyelination in cuprizone-treated mice. <i>NMR in Biomedicine</i> , 2015, 28, 327-337.	2.8	71
28	European Database for Myasthenia Gravis: A model for an international disease registry. <i>Neurology</i> , 2014, 83, 189-191.	1.1	8
29	Development of the MG-DIS: an ICF-based disability assessment instrument for myasthenia gravis. <i>Disability and Rehabilitation</i> , 2014, 36, 546-555.	1.8	18
30	VAV1 and BAFF, via NF $\kappa$ B pathway, are genetic risk factors for myasthenia gravis. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 329-339.	3.7	27
31	Altered miRNA expression is associated with neuronal fate in G93A-SOD1 ependymal stem progenitor cells. <i>Experimental Neurology</i> , 2014, 253, 91-101.	4.1	31
32	Increased expression KIR4.1 potassium channel in experimental models of demyelination. <i>Journal of Neuroimmunology</i> , 2014, 275, 108.	2.3	0
33	Innate immunity in myasthenia gravis thymus: Pathogenic effects of Toll-like receptor 4 signaling on autoimmunity. <i>Journal of Autoimmunity</i> , 2014, 52, 74-89.	6.5	62
34	A Superfluorinated Molecular Probe for Highly Sensitive <i>In Vivo</i> <sup>19</sup> F-MRI. <i>Journal of the American Chemical Society</i> , 2014, 136, 8524-8527.	13.7	113
35	Orphan drugs to treat myasthenia gravis. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 373-384.	0.8	1
36	Differential targeting of immune-cells by Pixantrone in experimental myasthenia gravis. <i>Journal of Neuroimmunology</i> , 2013, 258, 41-50.	2.3	3

#	ARTICLE	IF	CITATIONS
37	Complete stable remission and autoantibody specificity in myasthenia gravis. <i>Neurology</i> , 2013, 80, 188-195.	1.1	53
38	A New Thiopurine Sâ€Methyltransferase Haplotype Associated With Intolerance to Azathioprine. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 67-74.	2.0	21
39	Patient registries: useful tools for clinical research in myasthenia gravis. <i>Annals of the New York Academy of Sciences</i> , 2012, 1274, 107-113.	3.8	7
40	Recommendations for myasthenia gravis clinical trials. <i>Muscle and Nerve</i> , 2012, 45, 909-917.	2.2	122
41	Acetylcholine Receptor-Induced Experimental Myasthenia Gravis: What Have We Learned from Animal Models After Three Decades?. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2012, 60, 19-30.	2.3	30
42	An Optimized Method for Manufacturing a Clinical Scale Dendritic Cell-Based Vaccine for the Treatment of Glioblastoma. <i>PLoS ONE</i> , 2012, 7, e52301.	2.5	30
43	The thymus in myasthenia gravis: Site of â€œinnate autoimmunityâ€?. <i>Muscle and Nerve</i> , 2011, 44, 467-484.	2.2	56
44	Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies. <i>Neurology</i> , 2011, 76, 2079-2088.	1.1	71
45	Naturally Occurring CD4+CD25+ Regulatory T Cells Prevent but Do Not Improve Experimental Myasthenia Gravis. <i>Journal of Immunology</i> , 2010, 185, 5656-5667.	0.8	22
46	Detection of poliovirus-infected macrophages in thymus of patients with myasthenia gravis. <i>Neurology</i> , 2010, 74, 1118-1126.	1.1	51
47	Risk factors for tumor occurrence in patients with myasthenia gravis. <i>Journal of Neurology</i> , 2009, 256, 1221-1227.	3.6	29
48	Effect of IgG immunoadsorption on serum cytokines in MG and LEMS patients. <i>Journal of Neuroimmunology</i> , 2008, 201-202, 104-110.	2.3	28
49	Thymoma-associated myasthenia gravis: Outcome, clinical and pathological correlations in 197 patients on a 20-year experience. <i>Journal of Neuroimmunology</i> , 2008, 201-202, 237-244.	2.3	73
50	Pixantrone (BBR2778) Reduces the Severity of Experimental Autoimmune Myasthenia Gravis in Lewis Rats. <i>Journal of Immunology</i> , 2008, 180, 2696-2703.	0.8	10
51	The Kinesin Superfamily Motor Protein KIF4 Is Associated With Immune Cell Activation in Idiopathic Inflammatory Myopathies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 624-632.	1.7	20
52	Allorecognition of human neural stem cells by peripheral blood lymphocytes despite low expression of MHC molecules: role of TGF-Â in modulating proliferation. <i>International Immunology</i> , 2007, 19, 1063-1074.	4.0	53
53	Sa.21. Thymus of Myasthenic Patients with Thymitis and Thymic Involution Express High Levels of Toll-Like Receptor 4. <i>Clinical Immunology</i> , 2006, 119, S112.	3.2	0
54	Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2006, 172, 27-37.	2.3	103

#	ARTICLE	IF	CITATIONS
55	Immunomodulation of TGF-beta1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: Implications for antifibrotic therapy. <i>Journal of Neuroimmunology</i> , 2006, 175, 77-86.	2.3	114
56	Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice. <i>Neurological Research</i> , 2006, 28, 527-531.	1.3	34
57	Increased Toll-Like Receptor 4 Expression in Thymus of Myasthenic Patients with Thymitis and Thymic Involution. <i>American Journal of Pathology</i> , 2005, 167, 129-139.	3.8	58
58	Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association. <i>International Immunology</i> , 2004, 16, 559-565.	4.0	51
59	Breakdown of Tolerance to a Self-Peptide of Acetylcholine Receptor $\hat{\alpha}$ -Subunit Induces Experimental Myasthenia Gravis in Rats. <i>Journal of Immunology</i> , 2004, 172, 2697-2703.	0.8	70
60	Analysis of SjTREC Levels in Thymus from MG Patients and Normal Children. <i>Annals of the New York Academy of Sciences</i> , 2003, 998, 270-274.	3.8	2
61	Immunization with Rat-, but Not Torpedo-Derived 97-116 Peptide of the AChR $\hat{\alpha}$ -Subunit Induces Experimental Myasthenia Gravis in Lewis Rat. <i>Annals of the New York Academy of Sciences</i> , 2003, 998, 391-394.	3.8	5
62	Effect on T Cell Recognition and Immunogenicity of Alanine-Substituted Peptides Corresponding to 97-116 Sequence of the Rat AChR $\hat{\alpha}$ -Subunit. <i>Annals of the New York Academy of Sciences</i> , 2003, 998, 395-398.	3.8	4
63	Myasthenia Gravis (MG): Epidemiological Data and Prognostic Factors. <i>Annals of the New York Academy of Sciences</i> , 2003, 998, 413-423.	3.8	135
64	Video-assisted thoracoscopic extended thymectomy and extended transsternal thymectomy (T-3b) in non-thymomatous myasthenia gravis patients: remission after 6 years of follow-up. <i>Journal of the Neurological Sciences</i> , 2003, 212, 31-36.	0.6	126
65	Fibrogenic cytokines and extent of fibrosis in muscle of dogs with X-linked golden retriever muscular dystrophy. <i>Neuromuscular Disorders</i> , 2002, 12, 828-835.	0.6	51
66	Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. <i>Journal of Neuroimmunology</i> , 2002, 131, 179-185.	2.3	151
67	Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis. <i>Journal of Clinical Investigation</i> , 1999, 104, 1287-1295.	8.2	45
68	Identification of a Novel HLA Class II Association with DQB1*0502 in an Italian Myasthenic Population. <i>Annals of the New York Academy of Sciences</i> , 1998, 841, 355-359.	3.8	24
69	Anti-titin and Antiryanodine Receptor Antibodies in Myasthenia Gravis Patients with Thymoma. <i>Annals of the New York Academy of Sciences</i> , 1998, 841, 538-541.	3.8	35
70	Oral Administration of an Immunodominant TACHR Epitope Modulates Antigen-specific T Cell Responses in Mice. <i>Annals of the New York Academy of Sciences</i> , 1998, 841, 568-571.	3.8	2
71	Plasma Treatment in Diseases of the Neuromuscular Junction. <i>Annals of the New York Academy of Sciences</i> , 1998, 841, 803-810.	3.8	10
72	The expression of co-stimulatory and accessory molecules on cultured human muscle cells is not dependent on stimulus by pro-inflammatory cytokines: relevance for the pathogenesis of inflammatory myopathy. <i>Journal of Neuroimmunology</i> , 1998, 85, 52-58.	2.3	22

#	ARTICLE	IF	CITATIONS
73	Major histocompatibility complex class II molecule expression on muscle cells is regulated by differentiation: implications for the immunopathogenesis of muscle autoimmune diseases. <i>Journal of Neuroimmunology</i> , 1996, 68, 53-60.	2.3	24
74	T-Cell Receptor-CDR3 Sequences of Polymyositis Muscle-Infiltrating T-Lymphocytes Indicate a Conventional Antigen as Target. <i>Annals of the New York Academy of Sciences</i> , 1995, 756, 414-417.	3.8	1
75	T-Cell Infiltration in Polymyositis Is Characterized by Coexpression of Cytotoxic and T-Cell-Activating Cytokine Transcripts. <i>Annals of the New York Academy of Sciences</i> , 1995, 756, 418-420.	3.8	15
76	Presentation of endogenous acetylcholine receptor epitope by an MHC class II-transfected human muscle cell line to a specific CD4+ T cell clone from a myasthenia gravis patient. <i>Journal of Neuroimmunology</i> , 1993, 46, 57-65.	2.3	29
77	cDNA and Genomic Clones Encoding the Human Muscle Acetylcholine Receptor. <i>Annals of the New York Academy of Sciences</i> , 1993, 681, 165-167.	3.8	8
78	Approaches for Studying the Pathogenic T Cells in Autoimmune Patients. <i>Annals of the New York Academy of Sciences</i> , 1993, 681, 219-237.	3.8	33
79	HL A-A2-Restricted T-Cell Line Recognizing an Epitope of the Human Acetylcholine Receptor. <i>Annals of the New York Academy of Sciences</i> , 1993, 681, 276-279.	3.8	2
80	Analysis of T cell receptor repertoire of muscle-infiltrating T lymphocytes in polymyositis. Restricted V alpha/beta rearrangements may indicate antigen-driven selection.. <i>Journal of Clinical Investigation</i> , 1993, 91, 2880-2886.	8.2	143
81	Two isoforms of the muscle acetylcholine receptor $\epsilon$ -subunit are translated in the human cell line TE671. <i>FEBS Letters</i> , 1991, 295, 116-118.	2.8	29
82	A short plasma exchange protocol is effective in severe myasthenia gravis. <i>Journal of Neurology</i> , 1991, 238, 103-107.	3.6	64
83	Increased incidence of certain TCR and HLA genes associated with myasthenia gravis in Italians. <i>Journal of Autoimmunity</i> , 1990, 3, 431-440.	6.5	20
84	Anti AChR antibody: Relevance to diagnosis and clinical aspects of myasthenia gravis. <i>Italian Journal of Neurological Sciences</i> , 1988, 9, 141-145.	0.1	16
85	Use of immunoadsorbent columns for antiacetylcholine receptor antibody removal from plasma of myasthenia gravis patients. <i>Plasma Therapy and Transfusion Technology</i> , 1988, 9, 73-75.	0.2	1
86	Immunomodulatory Treatments for Myasthenia Gravis: Plasma Exchange, Intravenous Immunoglobulins and Semiselective Immunoadsorption. , 0, , .		0